119 related articles for article (PubMed ID: 25128670)
1. Present status of quinoxaline motifs: excellent pathfinders in therapeutic medicine.
Ajani OO
Eur J Med Chem; 2014 Oct; 85():688-715. PubMed ID: 25128670
[TBL] [Abstract][Full Text] [Related]
2. Quinoxaline, its derivatives and applications: A State of the Art review.
Pereira JA; Pessoa AM; Cordeiro MN; Fernandes R; Prudêncio C; Noronha JP; Vieira M
Eur J Med Chem; 2015 Jun; 97():664-72. PubMed ID: 25011559
[TBL] [Abstract][Full Text] [Related]
3. Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors.
Pissot-Soldermann C; Gerspacher M; Furet P; Gaul C; Holzer P; McCarthy C; Radimerski T; Regnier CH; Baffert F; Drueckes P; Tavares GA; Vangrevelinghe E; Blasco F; Ottaviani G; Ossola F; Scesa J; Reetz J
Bioorg Med Chem Lett; 2010 Apr; 20(8):2609-13. PubMed ID: 20231096
[TBL] [Abstract][Full Text] [Related]
4. Quinoxaline Moiety: A Potential Scaffold against
Montana M; Montero V; Khoumeri O; Vanelle P
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443334
[No Abstract] [Full Text] [Related]
5. Chemistry and pharmacological diversity of quinoxaline motifs as anticancer agents.
Ajani OO; Nlebemuo MT; Adekoya JA; Ogunniran KO; Siyanbola TO; Ajanaku CO
Acta Pharm; 2019 Jun; 69(2):177-196. PubMed ID: 31259731
[TBL] [Abstract][Full Text] [Related]
6. Quinoxalines Potential to Target Pathologies.
Tristán-Manzano M; Guirado A; Martínez-Esparza M; Gálvez J; García-Peñarrubia P; Ruiz-Alcaraz AJ
Curr Med Chem; 2015; 22(26):3075-108. PubMed ID: 26264925
[TBL] [Abstract][Full Text] [Related]
7. An insight into medicinal chemistry of anticancer quinoxalines.
Kaushal T; Srivastava G; Sharma A; Singh Negi A
Bioorg Med Chem; 2019 Jan; 27(1):16-35. PubMed ID: 30502116
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, in vitro antitubercular activity and 3D-QSAR of novel quinoxaline derivatives.
Puratchikody A; Natarajan R; Jayapal M; Doble M
Chem Biol Drug Des; 2011 Dec; 78(6):988-98. PubMed ID: 21951363
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a novel series of quinoxalines as inhibitors of c-Met kinase.
Porter J; Lumb S; Lecomte F; Reuberson J; Foley A; Calmiano M; le Riche K; Edwards H; Delgado J; Franklin RJ; Gascon-Simorte JM; Maloney A; Meier C; Batchelor M
Bioorg Med Chem Lett; 2009 Jan; 19(2):397-400. PubMed ID: 19059779
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of the antiproliferative activity of novel isoindolo[2,1-a]quinoxaline and indolo[1,2-a]quinoxaline derivatives.
Desplat V; Moreau S; Belisle-Fabre S; Thiolat D; Uranga J; Lucas R; de Moor L; Massip S; Jarry C; Mossalayi DM; Sonnet P; Déléris G; Guillon J
J Enzyme Inhib Med Chem; 2011 Oct; 26(5):657-67. PubMed ID: 21250818
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2.
Guillon J; Le Borgne M; Rimbault C; Moreau S; Savrimoutou S; Pinaud N; Baratin S; Marchivie M; Roche S; Bollacke A; Pecci A; Alvarez L; Desplat V; Jose J
Eur J Med Chem; 2013 Jul; 65():205-22. PubMed ID: 23711832
[TBL] [Abstract][Full Text] [Related]
12. Quinoxaline Nucleus: A Promising Scaffold in Anti-cancer Drug Discovery.
Pinheiro AC; Mendonça Nogueira TC; de Souza MV
Anticancer Agents Med Chem; 2016; 16(10):1339-52. PubMed ID: 27349448
[TBL] [Abstract][Full Text] [Related]
13. New ferrocenic pyrrolo[1,2-a]quinoxaline derivatives: synthesis, and in vitro antimalarial activity--Part II.
Guillon J; Mouray E; Moreau S; Mullié C; Forfar I; Desplat V; Belisle-Fabre S; Pinaud N; Ravanello F; Le-Naour A; Léger JM; Gosmann G; Jarry C; Déléris G; Sonnet P; Grellier P
Eur J Med Chem; 2011 Jun; 46(6):2310-26. PubMed ID: 21458112
[TBL] [Abstract][Full Text] [Related]
14. Quinoxaline: An insight into the recent pharmacological advances.
Tariq S; Somakala K; Amir M
Eur J Med Chem; 2018 Jan; 143():542-557. PubMed ID: 29207337
[TBL] [Abstract][Full Text] [Related]
15. 6H-Indolo[2,3-b]quinoxalines: DNA and protein interacting scaffold for pharmacological activities.
Moorthy NS; Manivannan E; Karthikeyan C; Trivedi P
Mini Rev Med Chem; 2013 Aug; 13(10):1415-20. PubMed ID: 23701655
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 6-({4-[2-(4-tert-butylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl}methyl)quinoxaline (WAY-207024): an orally active antagonist of the gonadotropin releasing hormone receptor (GnRH-R).
Pelletier JC; Chengalvala MV; Cottom JE; Feingold IB; Green DM; Hauze DB; Huselton CA; Jetter JW; Kopf GS; Lundquist JT; Magolda RL; Mann CW; Mehlmann JF; Rogers JF; Shanno LK; Adams WR; Tio CO; Wrobel JE
J Med Chem; 2009 Apr; 52(7):2148-52. PubMed ID: 19271735
[TBL] [Abstract][Full Text] [Related]
17. Gallium (III) triflate-catalyzed synthesis of heterocycles: quinoxalines, 1,5-benzodiazepines and their fluorinated derivatives.
Prakash GK; Vaghoo H; Venkat A; Panja C; Chacko S; Mathew T; Olah GA
Future Med Chem; 2009 Aug; 1(5):909-20. PubMed ID: 21426089
[TBL] [Abstract][Full Text] [Related]
18. Towards echinomycin mimetics by grafting quinoxaline residues on glycophane scaffolds.
Jarikote DV; Li W; Jiang T; Eriksson LA; Murphy PV
Bioorg Med Chem; 2011 Jan; 19(2):826-35. PubMed ID: 21195622
[TBL] [Abstract][Full Text] [Related]
19. New ferrocenic pyrrolo[1,2-a]quinoxaline derivatives: synthesis, and in vitro antimalarial activity.
Guillon J; Moreau S; Mouray E; Sinou V; Forfar I; Fabre SB; Desplat V; Millet P; Parzy D; Jarry C; Grellier P
Bioorg Med Chem; 2008 Oct; 16(20):9133-44. PubMed ID: 18819813
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of analogues of 7-chloro-4,5-dihydro-4- oxo-8-(1,2,4-triazol-4-yl)-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylic acid (TQX-173) as novel selective AMPA receptor antagonists.
Catarzi D; Colotta V; Varano F; Calabri FR; Filacchioni G; Galli A; Costagli C; Carlà V
J Med Chem; 2004 Jan; 47(1):262-72. PubMed ID: 14695840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
